Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

328.69 15.67 +5.01%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a

Charles River Laboratories International, Inc. 10-Q filed Aug 6, 2025

Fiscal Q2 2025 · Period ended Jun 28, 2025 · Filed · accepted 9:07 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2025: 22 added · 3 removed · 28 modified; 14 with only figures updated; 6 moved without change

  1. Modified · U.S. Government Investigations into the Non-Human Primate Supply Chain

    On February 17, 2023, we received a grand jury subpoena requesting certain documents related to an investigation by the U.S. Department of Justice (DOJ) and the U.S. Fish and Wildlife Service (USFWS) into our conduct regarding several shipments of non-human primates from Cambodia. That investigation remains ongoing in late 2022 and we are continuing to cooperate with early 2023 (the investigationNHP Shipments). As The DOJ also previously disclosed, undertook a parallel civil investigation is being undertaken by related to the DOJ and USFWSNHP Shipments. We are also cooperating with that investigation, and although we continue to dispute As previously disclosed, we continued to care for the NHP Shipments during the meritspendency of certain positions taken by the DOJ investigations. In July 2025, we were informed that USFWS had determined to clear the DOJNHP Shipments